Canada· CA-DIN-02403390
STIVARGA
A regorafenib product containing regorafenib, registered in Canada by BAYER INC. The same ATC class is registered in 13 of our 19 countries.
Checked against Health Canada Drug Product Database (Canada) on
Informational only — not a medical device.
Where it is registered
Regorafenib is registered in 13 of 19 countries.
Countries holding a registration under ATC L01EX05 (regorafenib), each read from that country’s own register.
- This record: Canada, from Health Canada Drug Product Database (Canada)
- 9 of them publish a price we can compare per daily dose
Regorafenib · ATC L01EX05
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of regorafenib costs, country by country.
Normalised to the WHO defined daily dose (0.12 g), so markets compare like for like.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Regorafenib · price per daily dose (0.12 g)
USD · FX 28 Sept 2026
- IT Italy$140.25
- CH Switzerland$139.52
The record
At a glance
Health Canada Drug Product Database (Canada)- Active substance
- REGORAFENIB
- Manufacturer
- BAYER INC
- Country
- Canada (CA)
- ATC code
- L01EX05
- ATC class
- Regorafenib
- Defined daily dose
- 0.12 g, O
- Reimbursed
- Not published by this register
- Source register
- Health Canada Drug Product Database (Canada)
- Last checked
- October 1, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
248 interactions on record for regorafenib.
Graded by severity as the source publishes them — 116 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Regorafenib · interactions on record
248 records
- 116 severe
- 125 moderate
- 7 minor
Most severe, free to view
- DicoumarolB01AA01severe
- WarfarinB01AA03severe
- HeparinB01AB01severe
- Antithrombin IIIB01AB02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Regorafenib in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomStivarga 40mg tabletsOriginalis B.V.
- FinlandStivargaParanova Oy
- CzechiaSTIVARGABayer AG, Leverkusen
- FranceSTIVARGA 40 mg, comprimé pelliculéBAYER AG (ALLEMAGNE)
- IrelandStivarga 40 mg film-coated tabletsBayer Pharma AG
- IcelandStivargaBayer AG*
- ItalySTIVARGA*3x28 cpr rivestite 40 mg flaconeBAYER AG
- NetherlandsStivarga 40 mg, filmomhulde tabletBayer AG
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Stivarga
- Liechtenstein · Stivarga
- Norway · Stivarga
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Health Canada Drug Product Database (Canada). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/fe9de55d-7c6a-4301-9202-5e1fbdab53d3 GET /v1/drugs/fe9de55d-7c6a-4301-9202-5e1fbdab53d3?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"din": "02403390",
"form": "TABLET",
"class": "Human",
"routes": [
"ORAL"
],
"source": "health_canada_dpd",
"status": "MARKETED",
"atc_raw": "L01EX05",
"schedule": [
"Prescription"
],
"drug_code": "88820",
"strengths": [
"40 MG"
],
"ahfs_class": null,
"substances": [
"REGORAFENIB"
],
"product_categorization": null
}See everything about regorafenib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.